search
Back to results

Improving Ultrasound Images in Brain Tumor Surgery With the Use of Brain Mimicking Fluid (BMF)

Primary Purpose

Brain Neoplasms, Glioma

Status
Completed
Phase
Phase 1
Locations
Norway
Study Type
Interventional
Intervention
brain mimicking fluid
Sponsored by
St. Olavs Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Brain Neoplasms focused on measuring ultrasonography, ultrasonics, brain, surgery

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • A glioblastoma is suspected when there is a solitary brain tumour with ring-like contrast enhancement and oedema with no recent history (last 3 years) of primary tumour elsewhere
  • In cases where histopathology is not known from previous biopsy or resection (i.e. diagnosis is suspected based on MRI findings and not from previous surgery) a tissue sample for frozen section is necessary. The fluid will only be used in cases where glioblastoma is suggested from this preliminary histopathological assessment.

Exclusion Criteria:

  • Intended biopsy only (meaning: cases not suitable for resection)
  • Other entities than glioblastoma is suspected
  • Allergy to diary products and marine products
  • Hypersensitvity to egg protein
  • Hypersensitivity to soya or peanut protein
  • Hypersensitvity to glycerol

Sites / Locations

  • Department of Neurosurgery, St Olavs Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

BMG

Arm Description

brain mimicking fluid

Outcomes

Primary Outcome Measures

adverse events
All adverse events registered but with special emphasis on: Intraoperatively -- epileptic seizures Immidiate postoperative -- hydrocephalus (MR images), imflammation of tissue that was in contact with AF (MR images)
adverse events
All adverse events registered but with special emphasis on: hydrocephalus (MR images) inflammation (MR images)
adverse events
All adverse events registered but with special emphasis on: hydrocephalus (MR images), inflammation (MR images)
adverse events
All adverse events registered but with special emphasis on: unusual clinical events, neurological deterioration or reduced consciousness

Secondary Outcome Measures

image quality
during the operation Qualitative score of ultrasound image quality (poor-medium-good) Qualitative score of artefacts in ultrasound images (none-some-much)
image signal-to-noise ratio
after the operation: image analysis by quantitative measurements of signal-to-noise ratio (SNR)

Full Information

First Posted
April 2, 2014
Last Updated
April 5, 2019
Sponsor
St. Olavs Hospital
Collaborators
National Competence Services for Ultrasound and Image-guided Therapy, SINTEF Health Research
search

1. Study Identification

Unique Protocol Identification Number
NCT02105233
Brief Title
Improving Ultrasound Images in Brain Tumor Surgery With the Use of Brain Mimicking Fluid
Acronym
BMF
Official Title
Brain Mimicking Fluid. Improving Ultrasound Images in Brain Tumor Surgery With the Use of Brain Mimicking Fluid: a Preliminary Technical and Safety Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
February 2014 (Actual)
Primary Completion Date
May 2016 (Actual)
Study Completion Date
May 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
St. Olavs Hospital
Collaborators
National Competence Services for Ultrasound and Image-guided Therapy, SINTEF Health Research

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Prognosis in patients with glioblastomas (the most aggressive high-grade glioma) remains unfavourable. Tools for improving brain tumor surgery, in particular for gliomas, are increasing. There seems to be an agreement that achieving extensive resections, when done safely without jeopardizing neurological function, improves survival. Ultrasound is currently used as a tool for providing 2D or 3D images for the purpose of tumor localization and resection control. For the use in resection control the resection cavity is filled with saline to provide acoustic coupling between the ultrasound transducer and tissue. However, attenuation of acoustic waves is very low in saline compared to the brain and this difference in attenuation is the cause of artifacts that may severely degrade the ultrasound images. Such artifacts are seen as high-intensity signal at the resection cavity wall and beyond, potentially masking small tumor remnants and generally making the interpretation of images more difficult. This research group has developed an acoustic fluid intended for use in the resection cavity instead of saline. Tests in laboratory measurements have shown that the fluid reduces artifacts and has the potential to enhance ultrasound image quality in brain tumor surgery. The investigators expect that the acoustic fluid will make it easier to detect small tumor remnants near the end of an operation, thus increasing success of glioma surgery. The purpose of this study is to test the fluid during surgery for histopathologically proven glioblastoma to assess safety and efficacy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Brain Neoplasms, Glioma
Keywords
ultrasonography, ultrasonics, brain, surgery

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BMG
Arm Type
Experimental
Arm Description
brain mimicking fluid
Intervention Type
Biological
Intervention Name(s)
brain mimicking fluid
Other Intervention Name(s)
acoustic fluid
Intervention Description
filled into the operation cavity during surgery for glioblastoma
Primary Outcome Measure Information:
Title
adverse events
Description
All adverse events registered but with special emphasis on: Intraoperatively -- epileptic seizures Immidiate postoperative -- hydrocephalus (MR images), imflammation of tissue that was in contact with AF (MR images)
Time Frame
1-72 hours
Title
adverse events
Description
All adverse events registered but with special emphasis on: hydrocephalus (MR images) inflammation (MR images)
Time Frame
1 month
Title
adverse events
Description
All adverse events registered but with special emphasis on: hydrocephalus (MR images), inflammation (MR images)
Time Frame
6 months
Title
adverse events
Description
All adverse events registered but with special emphasis on: unusual clinical events, neurological deterioration or reduced consciousness
Time Frame
up to 6 months
Secondary Outcome Measure Information:
Title
image quality
Description
during the operation Qualitative score of ultrasound image quality (poor-medium-good) Qualitative score of artefacts in ultrasound images (none-some-much)
Time Frame
1 day
Title
image signal-to-noise ratio
Description
after the operation: image analysis by quantitative measurements of signal-to-noise ratio (SNR)
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A glioblastoma is suspected when there is a solitary brain tumour with ring-like contrast enhancement and oedema with no recent history (last 3 years) of primary tumour elsewhere In cases where histopathology is not known from previous biopsy or resection (i.e. diagnosis is suspected based on MRI findings and not from previous surgery) a tissue sample for frozen section is necessary. The fluid will only be used in cases where glioblastoma is suggested from this preliminary histopathological assessment. Exclusion Criteria: Intended biopsy only (meaning: cases not suitable for resection) Other entities than glioblastoma is suspected Allergy to diary products and marine products Hypersensitvity to egg protein Hypersensitivity to soya or peanut protein Hypersensitvity to glycerol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Geir Bråthen, phd md
Organizational Affiliation
St. Olavs Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Department of Neurosurgery, St Olavs Hospital
City
Trondheim
Country
Norway

12. IPD Sharing Statement

Learn more about this trial

Improving Ultrasound Images in Brain Tumor Surgery With the Use of Brain Mimicking Fluid

We'll reach out to this number within 24 hrs